Blood Res.  2021 Jun;56(2):121-123. 10.5045/br.2021.2021040.

Polycythemia vera emerging eighteen years after acute myeloid leukemia diagnosis

• Langabeer SE
• O’Flynn DW
• Cahill MR

• KMID: 2517068
• DOI: http://doi.org/10.5045/br.2021.2021040

Figure

• 

  Fig. 1 Red blood cell indices of the patients throughout the clinical course.

Reference

1. Antonioli E, Guglielmelli P, Poli G, Santini V, Bosi A, Vannucchi AM. 2007; Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2 V617F clonal dominance. Blood. 110:4620–1. DOI: 10.1182/blood-2007-07-103267. PMID: 18056850.

2. Walker AR, Rothberg PG, Liesveld JL. 2007; A case of JAK2 positive essential thrombocythemia 16.5 years after autologous marrow transplantation for AML. Bone Marrow Transplant. 39:725–6. DOI: 10.1038/sj.bmt.1705647. PMID: 17401398.

3. Sato S, Itonaga H, Taguchi M, et al. 2018; Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm. Int J Hematol. 108:213–7. DOI: 10.1007/s12185-018-2419-1. PMID: 29417354.

4. Chabannon C, Bost M, Hollard D. 1994; A case of polycythemia vera occurring in a patient with acute non-lymphoblastic leukemia (ANLL) in long-term first complete remission. Leukemia. 8:1243–4. PMID: 8035619.

5. Belotti A, Doni E, Elli E, Rossi V, Pioltelli P, Pogliani EM. 2011; Development of polycythemia vera after chemotherapy-induced remission of acute myeloid leukemia: a case report. Acta Haematol. 126:52–3. DOI: 10.1159/000324468. PMID: 21454967.

6. Portell CA, Sekeres MA, Rogers HJ, Tiu RV. 2012; De novo polycythaemia vera arising 5 years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone. Br J Haematol. 157:266–7. DOI: 10.1111/j.1365-2141.2011.08972.x. PMID: 22150289.

7. Nielsen C, Bojesen SE, Nordestgaard BG, Kofoed KF, Birgens HS. 2014; JAK2 V617F somatic mutation in the general population: myeloproliferative neoplasms development and progression rate. Haematologica. 99:1448–55. DOI: 10.3324/haematol.2014.107631. PMID: 24907356. PMCID: PMC4562533.

8. McKerrell T, Park N, Chi J, et al. 2017; JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics. Blood Adv. 1:968–71. DOI: 10.1182/bloodadvances.2017007047. PMID: 29296738. PMCID: PMC5737599.

9. McKerrel T, Park N, Moreno T, et al. 2015; Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep. 10:1239–45. DOI: 10.1016/j.celrep.2015.02.005. PMID: 25732814. PMCID: PMC4542313.

10. Youk HJ, Cho CH, Lee JH, Choi CW, Lim CS, Yoon SY. 2014; A rare case of polycythemia vera following acute undifferentiated leukemia remission. Ann Lab Med. 34:469–70. DOI: 10.3343/alm.2014.34.6.469. PMID: 25368824. PMCID: PMC4215407.

11. Sutherland ND, Gonzalez-Peralta R, Douglas-Nikitin V, Hunger SP. 2004; Polycythemia vera in a child following treatment for acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 26:315–9. DOI: 10.1097/00043426-200405000-00012. PMID: 15111786.

12. Elli EM, Belotti A, Cecchetti C, et al. 2013; Development of JAK2 V617F-positive polycythemia vera after chemotherapy-induced remission of primary central nervous system diffuse large B cell non-Hodgkin's lymphoma: a case report and review of the literature. Acta Haematol. 130:142–5. DOI: 10.1159/000347159. PMID: 23652352.

13. Bartalucci N, Guglielmelli P, Vannucchi AM. 2020; Polycythemia vera: the current status of preclinical models and therapeutic targets. Expert Opin Ther Targets. 24:615–28. DOI: 10.1080/14728222.2020.1762176. PMID: 32366208.